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Research Article
Correlation of miRNA expression with
intensity of neuropathic pain in man
Diana Tavares-Ferreira1, Nathan Lawless2, Emma V Bird1,
Simon Atkins1, David Collier2, Emanuele Sher2, Karim Malki2,
Daniel W Lambert1, and Fiona M Boissonade1
Abstract
Background: Peripheral nerve injury causes changes in expression of multiple receptors and mediators that participate in
pain processing. We investigated the expression of microRNAs (miRNAs) – a class of post-transcriptional regulators
involved in many physiological and pathophysiological processes – and their potential role in the development or
maintenance of chronic neuropathic pain following lingual nerve injury in human and rat.
Methods: We profiled miRNA expression in Sprague-Dawley rat and human lingual nerve neuromas using TaqManVR
low-density array cards. Expression of miRNAs of interest was validated via specific probes and correlated with nerve
injury-related behavioural change in rat (time spent drinking) and clinical pain (visual analogue scale (VAS) score).
Target prediction was performed using publicly available algorithms; gene enrichment and pathway analysis were conducted
with MetaCore. Networks of miRNAs and putative target genes were created with Cytoscape; interaction of miRNAs and
target genomes in rat and human was displayed graphically using CircosPlot.
Results: rno-miR-138 was upregulated in lingual nerve of injured rats versus sham controls. rno-miR-138 and rno-miR-667
expression correlated with behavioural change at day 3 post-injury (with negative (rno-miR-138) and positive (rno-miR-667)
correlations between expression and time spent drinking). In human, hsa-miR-29a was downregulated in lingual nerve
neuromas of patients with higher pain VAS scores (painful group) versus patients with lower pain VAS scores (non-painful).
A statistically significant negative correlation was observed between expression of both hsa-miR-29a and hsa-miR-500a, and
pain VAS score.
Conclusions: Our results show that following lingual nerve injury, there are highly significant correlations between abun-
dance of specific miRNAs, altered behaviour and pain scores. This study provides the first demonstration of correlations
between human miRNA levels and VAS scores for neuropathic pain and suggests a potential contribution of specific miRNAs
to the development of chronic pain following lingual nerve injury. Putative targets for candidate miRNAs include genes
related to interleukin and chemokine receptors and potassium channels.
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Introduction
Pain perception forms part of a protective mechanism
against tissue damage, but if it evolves to a chronic state,
it may no longer serve a useful biological function and
can become severely disabling with significant impact on
quality of life.1 Neuropathic pain is defined as a type of
chronic pain that results from direct damage to the
peripheral or central nervous system (CNS).2 The precise
mechanisms behind the development and maintenance
of chronic pain after a peripheral nerve injury are not
fully understood. However, it is clearly established that
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nerve injury induces extensive complex changes at the
injury site including recruitment of immune cells, induc-
tion and release of multiple inflammatory mediators and
increased expression of a wide range of modulators of
neuronal excitability including neuropeptides and
voltage-gated ion channels.3–5 These events contribute
to the sensitisation of sensory neurons, the development
of altered excitability and the generation of spontaneous
ectopic neuronal firing at the injury site.4,6,7
Disorganisation of regenerating axons and development
of connective and scar tissue at the site of injury may
lead to the formation of a neuroma, where spontaneous
ectopic activity may continue to be generated for many
years after the initial injury. This activity produces spon-
taneous pain, a distinct characteristic of neuropathic
pain,5 and in addition is believed to drive central
change, further enhancing the chronicity of the pain.
Significant evidence now exists that microRNAs
(miRNAs) regulate a multiplicity of cellular processes,
including immune and inflammatory responses.6,8
miRNAs are small noncoding RNAs that regulate the
expression of multiple genes, predominantly by interact-
ing with the 30 untranslated region of messenger RNAs
(mRNAs).7 Neuropathic pain is characterised by alter-
ation in the expression of receptors and mediators (as
described above), and there is evidence that miRNAs
may contribute to some of these changes.9,10 For
instance, miR-9611 and miR-7a12 have been reported to
regulate the sodium channel Nav1.3, and the specific
deletion of Dicer (an enzyme required for the processing
of pre-miRNA) in dorsal root ganglia resulted in
changes in the expression of sodium channels Nav1.7,
1.8 and 1.9.13 Recent studies have demonstrated that
different miRNAs are expressed in different pain condi-
tions and that their expression changes over time. Tam
Tam et al.14 demonstrated that miR-143 expression is
decreased in dorsal root ganglion (DRG) in inflamma-
tory pain caused by injection of complete Freund’s adju-
vant (CFA), but not after transection of the sciatic
nerve. These studies indicate that as key regulators
that interact with several genes, miRNAs may be prom-
ising targets for the treatment of neuropathic pain.15
In this study, we have focused on the potential role of
altered miRNA expression in the development of pain
following lingual nerve injury, which can occur during
routine oral surgery or facial trauma. Patients with this
type of injury often report sensory alterations in the ipsi-
lateral side of their tongue including loss of taste (due to
the damage of gustatory afferents), hypoaesthesia
(decreased sensitivity to stimulation), paraesthesia
(abnormal sensations including tingling, itching) and
dysaesthesia (abnormal unpleasant sensations such as
burning and pain).16 If the symptoms are persistent,
patients are referred for surgical repair of the injured
nerve. Our centre provides a service for treatment of
patients with these injuries, including repair of the lin-
gual nerve, which has resulted in the collection of an
extensive archive of lingual nerve neuromas and their
associated clinical pain histories. Even though the over-
all outcome of the surgical repair is positive, when symp-
toms of dysaesthesia are present prior to repair, they
usually persist following surgery,17 and the pharmaco-
logical treatment of dysaesthesia (e.g. with gabapentin or
pregabalin) has limited success.16 In summary, to date,
the sequelae of nerve injury are not fully understood
and have not been therapeutically met18–20; thus,
further investigation of the underlying mechanisms of
neuropathic pain and the identification of novel
potential therapeutic targets are required.
The aim of this study was to investigate the expres-
sion of miRNAs in both human lingual nerve neuromas
and rat lingual nerve and to examine whether any
correlation exists between the expression of miRNAs
and clinical pain symptoms in patients or behavioural
change in animals. In this study, we have quantified
miRNA expression in human lingual nerve neuromas
and rat lingual nerves (following chronic constriction
injury (CCI) or sham injury) and correlated expression
with clinical pain and behavioural change. Subsequently,
we applied bioinformatics tools to predict potential
target genes and pathways under regulatory control of
the miRNAs identified. To our knowledge, this is the
first study to demonstrate that expression levels of spe-
cific miRNAs in human neuromas correlate with clinical
pain history and intensity.
Methods
Study design
A total of 18 adult male Sprague-Dawley rats (Charles
River, Margate, UK; 250–300 g) were used. All animals
were assessed for feeding behaviour (Ugo Basile
Orofacial Stimulation Test) on day 0 (baseline (BL),
before surgery) and on day 3 (after surgery; CCI or
sham procedure). We have previously established that
at this time point, there are high levels of spontaneous
neuronal activity (implicated in the development of neu-
ropathic pain21) and increased neuropeptide and sodium
channel expression at the injury site.22–32 Lingual nerve
samples were obtained from the injury site, or equivalent
site in sham-operated animals (CCI n¼ 3, sham proce-
dure n¼ 3), and processed for miRNA screening
using TaqManV
R
low-density array (TLDA) cards.
Specific miRNAs were selected and validated with
reverse transcription quantitative real-time polymerase
chain reaction (reverse transcription qPCR; RT-qPCR)
in the same six samples.
Seventeen human lingual nerve neuromas were
obtained from patients with lingual nerve injury
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undergoing treatment at the Charles Clifford Dental
Hospital, Sheffield, UK. These were divided into ‘pain-
ful’ (n¼ 8) and ‘non-painful’ (n¼ 9) based on the pain
visual analogue scale (VAS) score assessment conducted
by the clinician prior to nerve repair surgery. TLDA
miRNA screening was carried out on 12 human neuro-
ma samples (painful n¼ 6, non-painful n¼ 6) to identify
miRNAs linked to pain symptoms. Our previous
miRNA studies using primary cells33 indicated that
this should be achievable with this number of samples.
Specific miRNAs were selected and validated with
RT-qPCR in painful human neuromas (n¼ 8, six of
those used for TLDA screening with two additional
samples) and non-painful neuromas (n¼ 8, five of
those used for TLDA screening with three addition-
al samples).
Further bioinformatics analyses were performed
to predict potential target genes for the miRNAs
of interest.
Animal experiments
A total of 18 adult male Sprague-Dawley rats (250–300
g) were acquired from Charles River, UK, and kept in a
12-h light–dark cycle with free access to water and food.
All experiments were carried out in accordance with the
UK Home Office Animals (Scientific Procedures) Act,
1986. The ARRIVE guidelines34 have been followed in
reporting this study. The rat model of neuropathic pain
was adapted from Bennett and Xie.35 Under general
anaesthesia (isoflurane; 4% induction, 2%–3% mainte-
nance), the left lingual nerve was exposed and con-
stricted with two loosely tied 6/0 chromic catgut
sutures (CCI group; n¼ 9). In the sham group, the lin-
gual nerve was exposed but not injured (n¼ 9). The sub-
cutaneous tissue and overlying skin was closed with 4/0
vicryl sutures (Ethicon, Norderstedt, Germany).
Animals were randomly assigned to CCI or sham
group and left to recover for a period of three days fol-
lowing surgery. The feeding behaviour of these animals
was investigated before surgery and three days post-
surgery (see section below). At the end of the recovery
period, the animals were deeply anaesthetised with an
overdose of pentobarbitone and transcardially perfused
with cold phosphate-buffered saline to remove any pos-
sible blood-derived RNA/miRNA cross-contamination.
Tissues were collected quickly, snap frozen in liquid
nitrogen and subsequently stored at –80C until required
for further processing. In all cases, the time between
animal sacrifice and tissue snap freezing was less than
10 min.
Behavioural testing
The effect of lingual nerve injury on feeding behaviour
was measured using the Orofacial Stimulation Test (code
31300, Ugo Basile, Comerio, VA, Italy).36 Briefly, the
animals (n¼ 18) voluntarily inserted the snout through
an opening and used the tongue (which is innervated by
the lingual nerve) to access a reward (chocolate milk)
from a bottle. The equipment automatically measured
the duration of feeding over a given period of time
(‘time spent drinking’), independently of investigator
bias. One week prior to the surgery, animals were trained
to use the behavioural equipment. Sessions consisted of
a 10-min acclimatisation period plus a further 10-min
recording with access to the reward bottle. Behavioural
assessment took place immediately before the surgery
(day 0) and on day 3 after surgery. In total, 18 animals
were used for behavioural testing, but only 6 animals
(CCI n¼ 3; sham n¼ 3) were used for the purpose of
the miRNA study reported here.
Human lingual nerve neuroma samples
Neuromas used in this study were obtained from the
archive of lingual nerve neuromas collected from the
Charles Clifford Dental Hospital, Sheffield, UK. All
neuromas were collected with the written informed con-
sent of the patients. The study was conducted in accor-
dance with ethical approvals received from the South
Sheffield Research Ethics Committee (06/Q2305/151
STH13926) and the East of England – Cambridge
Central Research Ethics Committee (17/EE/0238 STH
19847). The pain history and symptoms (pain, tingling,
or discomfort on the side of the tongue innervated by the
injured nerve) were obtained by the clinician preopera-
tively. In addition, patients were also asked to score
the discomfort, tingling and pain using VAS score.
A detailed description of the surgical removal of the
neuroma, repair of the nerve and collection of clinical
history has been described previously.17 Based on the
pain VAS scores, the neuromas chosen for this study
were divided in two groups: ‘painful’ (pain VAS score
higher than 30) and ‘non-painful’ (pain VAS score lower
than 8). Human tissue preparation was performed fol-
lowing previously published protocols by Bird et al.37
After surgical removal, the neuromas were placed in
2% Zamboni’s fixative (0.1 mol/L phosphate buffer,
pH 7.4, containing 4% paraformaldehyde and 0.2%
picric acid) for 24 h at 4C, subsequently cryoprotected
in 30% sucrose solution for 12 h at 4C and stored
at –80C.
miRNA extraction and TLDA cards
Rat lingual nerve tissue was disrupted and miRNA iso-
lated using the mirVana miRNA Isolation Kit
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(ThermoFisher, Paisley, UK) according to the manufac-
turer’s protocol. Human neuroma tissue miRNA was
isolated using the RecoverAll Total Nucleic Acid
Isolation Kit (ThermoFisher). As the samples used
were frozen and not embedded in paraffin, the deparaffi-
nisation step was omitted from the manufacturer’s
protocol. Instead, prior to extraction, human tissue sam-
ples were stored in RNAlater-ICE Frozen Tissue
Transition Solution (ThermoFisher) overnight at –20C,
to facilitate the thawing of the tissue while preserving
RNA quality.
miRNA expression profiles were initially screened
using TLDA Rodent miRNA Cards v.3 A and B, and
TLDA Human miRNA Cards v.3 A and B, respectively,
for rat and human lingual nerve samples. Each card held
up to 381 preloaded miRNA probes and endogenous
controls (according to the miRBase database,38 there
are currently 496 verified rat miRNA sequences and
1,917 verified human miRNA sequences). All samples
were reverse-transcribed using the TaqMan miRNA
Reverse Transcription kit (ThermoFisher) and preampli-
fied (12 cycles) using TaqMan PreAmp master mix and
primers, prior to being loaded into the respective TLDA
microfluidic cards following the manufacturer’s protocol.
miRNA validation
The expression of miRNAs of interest selected in the
TLDA screening was validated using TaqMan miRNA
Assays (triplicate per sample) and performed in a Rotor
Gene real-time PCR machine (Qiagen, Manchester, UK).
After reverse transcription and preamplification with spe-
cific TaqMan probes for the miRNAs of interest and
endogenous control (snRNAU6), Rotor-Gene 2.1.0.9 soft-
ware (Qiagen) was used to set the qPCR reaction (initial
enzyme activation at 95C for 10 min, and cycling condi-
tions defined at 95C for 15 s followed by 60C for 60 s, for
40 cycles). A no-template control (no PreAmp product)
sample was added to test for cDNA contamination.
Statistical analyses
Rat behavioural testing. The results of the Orofacial
Stimulation Test (time spent drinking) were evaluated
statistically: a paired t test (two-tailed, equal variances
assumed) was used to evaluate differences within the
CCI and sham groups, comparing results at day 3 with
the BL; differences between groups at BL (before sur-
gery) were evaluated using an unpaired t test (two-tailed,
equal variances assumed). In addition, Pearson’s corre-
lations were applied to investigate the relation between
miRNA expression and time spent drinking.
Patient clinical variables. Differences in VAS scores
between painful and non-painful groups were evaluated
using an unpaired t test with equal variance assumed.
Pearson’s correlation was used to test the association
between pain VAS score and discomfort VAS score,
and between miRNA expression and pain, tingling and
discomfort VAS scores.
Analysis of TaqMan miRNA array data and miRNA validation
PCR. For both human and rat TLDA array cards, the
delta Ct normalisation method was applied and the
snRNAU6 endogenous control used. Prior to normal-
isation, any miRNA not detected in two of either
the experimental or control samples was removed from
further analysis. The unpaired t test was performed to
calculate statistical differences between groups.
For qPCR validation of miRNAs of interest selected
during TLDA screening, the comparative delta-delta Ct
(2(–DDCt)) method was used. First, delta Ct (DCt) values
for each miRNA were obtained after normalising to
snRNAU6. The relative expression for each miRNA in
the experimental lingual nerve (CCI in the rat tissue and
painful group in the human tissues) was compared with
that in the control lingual nerves (sham in the rat tissues
and non-painful in the human tissues) and calculated
using the expression 2DDCt, where
DDCt¼DCt(experimental) – DCt (control). Results were
considered statistically significant with p< 0.05.
Target prediction and enrichment analysis
Target genes potentially regulated by miRNAs of inter-
est were predicted using the consensus of three publicly
available miRNA target databases: TargetScan (http://
www.targetscan.org),39 MicroCosm (http://www.ebi.ac.
uk/enright-srv/microcosm),40 and miRTarBase (http://
mirtarbase.mbc.nctu.edu.tw).41 The predicted target
false-positive rate was reduced significantly by applying
a cut-off of –0.4 in the contextþþ scores for TargetScan
results42; each miRNA target was cross-referenced
against this gene set. Enrichment and pathway analysis
of predicted miRNA gene targets was undertaken using
MetaCoreTM process networks, pathway maps and GO
molecular functions/processes. Top pathways were
ranked based on z-score and the additional enriched
gene count per pathway. Interactions between
miRNAs and their target gene networks for each tissue
were visualised using CyTargetLinker v3.0.1, an open
source software package for Cytoscape v.4.0.43 Circos
v0.67 was used to display interaction between miRNAs
and target genes in a circular layout, facilitating the visu-
alisation of the position of the miRNAs and target genes
in the respective genome44; only target genes passing the
described cut-off were visualised in the CircosPlot.
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Results
Rat lingual nerve tissues
Behavioural testing. Evaluation of the effect of surgery on
the feeding behaviour (time spent drinking) within each
group showed a significant decrease following injury in
the experimental CCI group on day 3 compared with BL
(t¼ 5.003, df¼ 8, p¼ 0.001; paired t test) (Figure 1(a)).
In the sham group, no statistical differences were found
on day 3 compared with BL (t¼ 2.2025, df¼ 8,
p¼ 0.0775; paired t test) (Figure 1(b)). There were no
statistical differences in BL values between groups
(t¼ 0.658, df¼ 16, p¼ 0.5199; unpaired t test).
miRNA expression in rat lingual nerve
We identified five miRNAs differentially expressed in the
rat lingual nerve (Table 1). These five miRNAs sequences
from the rodent TLDA cards were selected based on
higher DDCt values and lower p value (p< 0.05). Two
of these miRNAs were selected for miRNA validation:
rno-miR-138 (upregulated in the CCI group vs. sham)
and rno-miR-667 (downregulated in the CCI group).
As TLDA cards for rodent miRNA analysis include
probes for both rat and mouse, these two miRNAs
were selected because they were confirmed in the
miRBase database as being present in the rat genome.
The same rat lingual nerve samples were used for
miRNA validation. In the validation study, only miR-
138 expression was found to be significantly different
(increased in the CCI vs. the sham group) at day 3
post-injury (miR-138: t¼ 3.125, df¼ 4, p¼ 0.0353,
unpaired t test; miR-667: t¼ 2.501, df¼ 4, p¼ 0.0667,
unpaired t test) (Figure 2(a)). However, a significant cor-
relation was found between the normalised delta Ct and
the time spent drinking for both miR-138 (positive cor-
relation r¼ 0.8511, p¼ 0.0316, reflective of a negative
correlation between abundance of miR-138 and time
spent drinking) and miR-667 (negative correlation
r¼0.9327, p¼ 0.0066, reflective of a positive correla-
tion between abundance of miR-667 and time spent
drinking) (Figure 2(b, c)).
miRNA target prediction and gene
enrichment analysis
We next sought to identify potential functional conse-
quences of altered expression of the candidate miRNAs.
Given the correlation results obtained, we conducted
target prediction and gene enrichment analyses for
both rno-miR-138 and rno-miR-667. The first step was
to use publicly available algorithms to look for predicted
target genes of the identified miRNAs. We used
TargetScan, MicroCosm and miRTarBase included in
the CyTargetLinker app to build a miRNA-target gene
network (Figure 3(a)). The target genes chosen for fur-
ther analysis were ranked by the cumulative weighted
contextþþ scores of TargetScan applying a cut-off of
–0.4,39,42 resulting in 119 target genes for rno-miR-138
and 91 for rno-miR-667. rno-miR-138 is located on
chromosome 8 of the rat genome and rno-miR-667 is
located on chromosome 6, and the target genes are locat-
ed on different chromosomes across the rat genome
Figure 1. Box plot showing total time spent drinking within each
group, comparing three days after injury/sham with BL. (a) In the
CCI group, time spent drinking was significantly reduced on day 3
compared with BL (**p¼ 0.001; paired t test). (b) In the sham
group, no statistical differences in the time spent drinking were
found between BL and day 3 (ns; paired t test).
CCI: chronic constriction injury; BL: baseline; ns: not significant.
Table 1. miRNAs differentially expressed in the rat lingual nerve.
miRNA DDCt p value
rno-miR-667 8.55 0.03
rno-miR-138 –9.12 0.0002
mmu-miR-1957 –10.04 0.05
mmu-miR-1904 8.50 0.0002
mmu-miR-1951 12.22 0.005
Rat miRNA TLDA samples were analysed using the unpaired t test.
miRNA: microRNA.
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(Figure 3(b)). Gene enrichment and pathway analysis
were carried out using MetaCoreTM process networks,
pathway maps, GO molecular functions and GO biolog-
ical processes.
Examples of genes targeted by the miRNAs and
enriched for these pathways are listed in Table S1
(please see supplementary files). The MetaCore Process
networks identified seven main networks. These included
neurophysiological process transmission of nerve
impulse, Wnt signal transduction, cell adhesion, chemo-
taxis, calcium transport, inflammation and neutrophil
activation and neuropeptide signalling pathways.
The MetaCore pathway maps were enriched for cell
adhesion and chemokines. MetaCore diseases and bio-
markers enrichment analysis detected epilepsy and
mouth diseases. The enrichment analysis for GO biolog-
ical process included regulation of transmembrane
transport, regulation of ion transport, interleukin (IL)-
8-mediated signalling pathway and T cell chemotaxis.
The GO molecular function identified ion transmem-
brane transporter activity, voltage-gated cation channel
activity, potassium channel activity and ion chan-
nel binding.
Potential novel rat miRNAs
The rodent TLDA cards are designed to specifically
detect 373 rat and 641 mouse miRNAs. In the rat lingual
nerve samples analysed, eight miRNA sequences were
detected that have only been reported in the mouse (as
in accordance with the miRBase database). However, a
sequence blast against the rat genome detected a high
similarity for the stem-loop precursor and mature
sequences of two of these miRNA sequences, miR-
1904 and miR-763; one of these (miR-1904) was found
to be differentially expressed between CCI and sham
groups (tool available at https://blast.ncbi.nlm.nih.gov/
Blast.cgi). The stem-loop sequence of miR-1904 is locat-
ed on chromosome 13 of the mouse genome, and it was
identified as a high similarity sequence for the rat
genome on chromosome 2 with only two mismatches
(p¼ 1e-27, ident: 97%). The mature sequence (22 nucleo-
tides) corresponds to nucleotide 11 to 32 of the stem-
loop and presents a mismatch outside the seed region
on the position 12 (p¼ 0.18, ident: 95%).
The miR-763 stem-loop sequence is located on chro-
mosome 10 of the mouse genome. A high similarity on
chromosome 7 on the rat genome with 3 mismatches
(p¼ 5e-48, ident: 97%) was found. The mature
miRNA sequence comprises nucleotides 38 to 59 and
has an exact match in the rat genome (p¼ 8e-04,
ident: 100%).
It is possible that these represent novel rat miRNAs;
however, further experimentation required to provide
validation of this (as per miRBase criteria) is beyond
the scope of this study.
Figure 2. miRNA validation and correlation scatter plots. (a) miR-
138 was confirmed to be statistically significantly differentially
expressed between sham and CCI group (increased in the CCI
group vs. sham; *p< 0.05; unpaired t test). miR-667 was not sta-
tistically differentially expressed in the miRNA validation study (ns;
unpaired t test). (b) Pearson’s correlations showed a strong corre-
lation between the expression of miR-138 and the time spent
drinking on day 3 (r¼ 0.8511, p¼ 0.0316). (c) Pearson’s correlations
showed a strong correlation between the expression of miR-667
and the time spent drinking on day 3 (r¼ –0.9327, p¼ 0.0066). In
(b) and (c), miRNA values are provided in terms of normalised delta
Ct values (DCt); the higher the Ct value, the lower the expression
of the miRNA; thus, the expression of miR-138 is strongly negatively
correlated, and the expression of miR-667 is strongly positively
correlated with the time spent drinking on day 3.
CCI: chronic constriction injury; ns: not significant.
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Figure 3. Rat miRNAs of interest and respective putative target genes. (a) CyTargetLinker analysis and network visualisation of differentially
expressed rat miRNAs and their predicted target genes. Network enrichment genes for rno-miR-138 and rno-miR-667 were identified using
MicroCosm, TargetScanHuman and miRTarBase. Nodes coloured in blue are targets of rno-miR-138, and nodes coloured in green are targets
of rno-miR-667. The nodes coloured in yellow are targets of both rno-miR-138 and rno-miR-667, while nodes in red are genes known to
have a role in pain. This network was constructed and visualised using CyTargetLinker v3.0.1 and Cytoscape v3.4.0, and there is no relation
between the position of the nodes and the score of the target prediction. (b) Circos v0.67 plot of rno-miR-138 (blue) and rno-miR-667
(green) and regulatory target genes. The middle track represents the rat genome with each ideogram segment representing one chromo-
some. The outermost and inner tracks display the gene name and spatial location of each gene targeted by both rat miRNAs.
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Human lingual nerve neuromas
Analysis of clinical characteristics. Clinical variables were
explored to test difference in VAS scores between
patients. Patients in the non-painful group reported an
average pain VAS score of 2.89, which is generally
considered as no pain.45 Patients in the painful group
had VAS scores ranging between 30 and 95, with an
average of 55.13. Overall, there was a significant differ-
ence in the pain VAS score between the high and low
pain groups (t¼ 6.29, df¼ 15, p< 0.0001). Pain VAS
score was found to be significantly correlated with
VAS scores on discomfort (Pearson’s r¼ 0.5, p¼ 0.05)
(Figure 4). No relationship was found between tingling
and pain, nor between tingling and discomfort (Table 2).
miRNA expression analysis
We identified two miRNAs, hsa-miR-29a and hsa-miR-
500a, that were differentially expressed in painful and
non-painful human lingual nerve neuromas in the
TLDA screening analysis (Table 3). qPCR validation
was conducted for these two miRNAs: miR-29a was
found to be differentially downregulated in the painful
group compared with the non-painful group (t¼ 2.76,
p¼ 0.02; unpaired t test), while miR-500a was not sta-
tistically significantly different between the groups
(Figure 5(a)). However, a significant positive correlation
was found between delta Ct and the pain VAS score for
both miRNA-29a (r¼ 0.75, p¼ 0.0007) and miRNA-
500a (r¼ 0.65, p¼ 0.006) (Figure 5(b)), reflective of a
negative correlation between abundance of these
miRNA and pain. No correlation between tingling or
discomfort and miRNA expression was observed.
miRNA target prediction and gene
enrichment analysis
Similarly to the process performed for the rat miRNAs,
we also used the same publicly available databases to
look for predicted target genes of the identified human
miRNAs; both hsa-miR-29a and hsa-miR-500a were
further analysed, given the correlation results. For visu-
alisation purposes, the miRNA-target gene networks
were again created with the CyTargetLinker app from
Cytoscape, as represented in Figure 6(a). The gene tar-
gets chosen for further analysis were ranked by the
cumulative weighted contextþþ scores of TargetScan
(cut-off –0.4) resulting in 67 predicted targets for hsa-
miR-29a and 115 for hsa-miR-500a. The predicted target
genes are located across different chromosomes in the
human genome (see Figure 6(b)), but both miRNAs
Figure 4. Correlation between pain and discomfort VAS scores.
Pearson’s correlations showed a significant positive correlation
between pain and discomfort VAS scores (r¼ 0.5, p¼ 0.05).
VAS: visual analogue scale.
Table 2. Clinical characteristics of the patients included in
the study.
Neuroma
sample
Age
(years) Sex
Time after
injury
(months)
Pain
VAS
Tingling
VAS
Discomfort
VAS
Non-painful
1a 42 F 20 0 33 10
2 36 F 24 0 25 79
3 27 F 5 1 1 81
4 38 F 10 3 10 38
5 60 M – 4 7 6
6 59 F 8 5 38 58
7b 31 F 10 0 8 95
8b 47 F 8 5 94 89
9b 44 F 12 8 6 83
Painful
10 35 F 6 30 6 60
11 38 M 48 30 97 83
12 30 F 12 35 75 64
13 54 F 36 60 11 98
14 44 F 7 82 85 100
15 44 F 9 95 3 97
16b 29 F 12 42 0 70
17b 47 F 10 67 100 77
Data missing for time after injury for neuroma sample 5.
F: female; M: male; VAS: visual analogue scale; miRNA: microRNA.
aSample used only in miRNA screening.
bSample used only in miRNA validation (all other samples were used for
both miRNA screening and validation).
Table 3. miRNA differentially expressed in human lingual
nerve neuromas.
miRNA DDCt p value
hsa-miR-29a 6.22 0.001
hsa-miR-500a 5.70 0.020
Human miRNA TLDA samples were analysed using the unpaired t test.
miRNA: microRNA.
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share a number of common target genes. hsa-miR-500 is
located on chromosome X, and hsa-miR-29a is located
on chromosome 7 of the human genome.
Enrichment and pathway analysis were carried out
using MetaCoreTM process networks, pathway maps,
GO molecular functions and GO biological processes
for the human miRNA target genes identified.
Examples of genes potentially targeted by the miRNAs
and enriched for these pathways are listed in Table S2.
Here, we report the most relevant pathways in the con-
text of pain, nerve injury and inflammation. MetaCore
process networks identified three main pathways: inflam-
mation (Jak-STAT), potassium transport and chemotax-
is. MetaCore pathway maps included IL-16 signalling
pathway, IL-15 signalling via JAK-STAT cascade and
impaired lipoxin A4 signalling. The enrichment analysis
for GO biological process included regulation of trans-
membrane transport, G protein-activated inward rectifi-
er potassium channel activity and macrophage apoptotic
process; and negative regulation of leukocyte activation,
leukocyte cell–cell adhesion, cell activation, cell growth
and cell proliferation. GO molecular function identified
several clusters associated with inflammation and ion
and membrane transport including: IL-2 receptor activ-
ity and binding; cytokine receptor activity; ion channel
activity; voltage-gated ion channel activity; transmem-
brane, substrate-specific and passive transmembrane
transporter activity.
Discussion
Major findings
The following were the main findings of this study:
1. rno-miR-667 was increased in the lingual nerve of
injured rats (CCI group) compared with sham control
rats.
2. The abundance of rno-miR-138 and rno-miR-667 was
found to be statistically significantly correlated (neg-
atively and positively, respectively) with the time
spent drinking on day 3 post-injury. A reduction in
time spent drinking may indicate hypersensitivity to
stimulation of the tongue (or other intraoral regions);
thus, these data suggest that increased levels of
rno-miR-138 and decreased levels of rno-miR-667
may be associated with presence of nerve injury-
induced hypersensitivity.
3. hsa-miR-29a expression was reduced in lingual nerve
neuromas of patients with higher pain VAS scores
(painful group), compared with patients with lower
pain VAS scores (non-painful group).
4. A statistically significant negative correlation was
observed between the expression of both hsa-
miR-29a and hsa-miR-500a, and the pain VAS
score, indicating that reduced levels of both these
miRNAs are associated with the presence of pain.
5. Target and gene enrichment analysis predicted that all
the above miRNAs may target genes involved in
inflammatory and pain-related pathways.
Figure 5. miRNA validation and correlation scatter plots. (a)
miR-29a was confirmed to be statistically significantly differentially
expressed (downregulated) in the painful group versus the non-
painful group (*p¼ 0.02; unpaired t test). miR-500a was relatively
downregulated in the painful group, but no statistical differences
were found (ns; unpaired t test). (b and c) Pearson’s correlations
showed a moderate inverse correlation between the expression of
miR-29a and miR-500a, and the pain VAS scores (r¼ 0.7544,
p¼ 0.0007 and r¼ 0.6515, p¼ 0.0063, respectively). In (b) and (c),
miRNA values are given in terms of normalised DCt values, where
the higher the Ct value, the lower the expression of the miRNA.
ns¼ not significant; VAS: visual analogue scale.
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Figure 6. Human miRNAs of interest and respective putative target genes. (a) CyTargetLinker analysis and network visualisation of
differentially expressed human neuromas miRNAs and their predicted target genes. Network enrichment genes for hsa-miR-29a and hsa-
miR-500a were identified using MicroCosm, TargetScanHuman and miRTarBase. Nodes coloured in blue are targets of hsa-miR-29a, and
nodes coloured in green are targets of hsa-miR-500a. The nodes coloured in yellow are targets of both hsa-miR-29a and hsa-miR-500a,
while nodes in red are genes known to have a role in pain. This network was constructed and visualised using CyTargetLinker v3.0.1 and
Cytoscape v3.4.0. (b) Circos v0.67 plot of hsa-miR-29a (blue) and hsa-miR-500a (green) and regulatory target genes. The middle track
represents the human genome with each ideogram segment representing one chromosome. The outermost and inner tracks display the
gene name and spatial location of each gene targeted by both human miRNAs.
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miRNAs and hyperalgesic states
A range of previous studies have linked expression of
miR-138, miR-667, miR-29a and miR-500 with changes
related to nerve injury, other hyperalgesic states and
neuroplasticity. It is difficult to directly compare these
findings with those of the present study as there are
differences in the models used, the time course and
sites of assessment of miRNA expression, but these ear-
lier studies do provide further evidence that the miRNAs
identified in the present study may play a significant role
in responses to nerve injury, hyperalgesia and neuroplas-
ticity. The findings from these studies are summar-
ised below.
miR-138. Work by Strickland et al.46 reports a downregu-
lation in miR-138 in the rodent DRG seven days follow-
ing sciatic nerve transection. miR-138 has also been
linked more broadly with neuroplasticity. It is known to
be highly expressed in brain synapses and has been shown
to target the depalmitoylation enzyme acyl-protein thio-
esterase 1, which has been linked to the regulation of
dendritic spine size in rat hippocampal neurons.47
miR-667. Previous studies also implicate altered miR-667
expression in the development of hyperalgesia. Lentiviral
injections of this miRNA increase hypersensitivity in the
mouse formalin model,48 a model of inflammatory pain.
This is thought to be linked to the ability of miR-667 to
reduce levels of catechol-O-methyltransferase (Comt)
mRNA in the brain.48 COMT degrades catecholamines
such as dopamine and epinephrine, and low levels of this
enzyme have been associated with hyperalgesic states.49
miR-29a. Rodent studies report that miR-29a is
decreased in spinal cord dorsal horn seven days after
injury (CCI) to rat sciatic nerve.50 This miRNA has
also been shown to be downregulated in the ipsilateral
trigeminal ganglion 4 h after administration of CFA in a
model of inflammatory muscle pain.51 miR-29a has also
been associated with inflammatory pain conditions in
man. It has been found in blood microvesicles, small
bowel and colon tissues of irritable bowel syndrome
patients. Its presence has been associated with increased
intestinal permeability (linked with chronic visceral
pain); inhibition of miR-29a expression in vitro restored
intestinal permeability to normal levels.52
miR-500. It has been reported that miR-500 is downregu-
lated in rat DRG after sciatic nerve resection at 4, 7 and
14 days53 and in the spinal cord dorsal horn neurons
7 days after CCI of sciatic nerve.50 How this relates to
neuropathic pain is not yet clear, but there is some evi-
dence that miR-500 downregulates the neurokinin-1
(substance P) receptor.54 Activation of this receptor by
substance P produces mechanical hyperalgesia and allo-
dynia,55 and these molecules have been implicated in neu-
ropathic pain. Studies in our and others’ laboratories
have shown that substance P accumulates at sites of
nerve injury, including trigeminal nerve injury27,28 and
application of substance P at these sites increases sponta-
neous activity.26 In another rodent study, miR-500 was
shown to be increased after administration of paclitaxel
or L5 ventral root transection and modulated the down-
regulation of glutamic acid decarboxylase 67 (GAD67),56
an enzyme that regulates the function of GABAergic syn-
apses in spinal cord dorsal horn neurons. In the same
study, miR-500 knockout or the use of an antagomir
led to functional repair of GABAergic synapses and alle-
viated pain behaviour in rats, suggesting that miR-500
negatively contributes to GABAergic synaptic function
through the regulation of GAD67. Other rodent studies
have shown that miR-500 is expressed in the CNS, and it
is thought to have a major role in CNS development.57
Studies in man also indicate a link between miR-500
and pain symptoms. Work conducted using human
whole blood samples collected from patients with com-
plex regional pain syndrome (CRPS) demonstrated that,
even though miR-500 was not significantly altered
between CRPS patients and controls, the levels of this
miRNA were negatively correlated with the symptoms
of hypoaesthesia.58 The miR-500 gene is located on
chromosome X, and it is of interest that the majority
of patients in the present study were female (Table 2).
Recent evidence by Linnstaedt et al.59 shows miRNAs
enriched for chromosome X in patients with persistent
musculoskeletal pain, suggesting that miRNAs can play
a role in sex-specific pain differences. There have also
been some studies associating miRNAs in the X chro-
mosome with potential sex-specific immune responses,60
and it has been shown that in several mammalian spe-
cies, the Y chromosome has no miRNA genes. Further
studies are required to elucidate the potential role of
miRNAs in general, and miR-500a in particular, in
sex-specific pain differences.
Predictive target analysis
Potential cell types expressing miRNAs and predicted targets.
The enrichment analysis of both rat and human
miRNAs identified a wide range of predictive target
genes involved in a range of processes including inflam-
mation, chemotaxis, signal transduction and ion trans-
membrane transport. These processes are all influenced
by tissue or nerve injury and can directly activate and/or
sensitise nociceptors facilitating the transmission of noci-
ceptive input61; they are thus potentially relevant to the
development of neuropathic pain. The injured rat lingual
nerves and human neuroma samples contain a range of
structures. These include nerve axons, Schwann cells,
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fibroblasts, macrophages and other leukocytes.37,62
Further studies are required to identify which cell types
are expressing the miRNAs shown to correlate with
behavioural change and VAS scores for pain in the cur-
rent study, but altered miRNA expression in any of the
cell types listed above, or altered miRNA expression as a
consequence of any change in the cell types present in the
tissue (e.g., due to immune cell infiltration), has potential
to impact on the development of pain. The neuronal
somas and nuclei are not present in the rat and human
nerve tissues used in this study; however, there is clear
evidence that both neuronal miRNAs and mRNAs are
present in neuronal axons.63,64 Of particular relevance to
the findings from the present study, miR-138 and
miR-29a are both reported to be abundantly expressed
in sensory axons.65
Predictive targets of rodent miRNAs. Genes related to inflam-
mation and chemotaxis that are thought to play key
roles in nociceptive processing and neuropathic pain
and are predictively targeted by rno-miR-138 and rno-
miR-667 include the c-c motif chemokine ligand 3 (Ccl3,
predictively targeted by rno-miR-138 with a 8mer canon-
ical binding) and the c-x-c motif chemokine receptor 1
(Cxcr1, also known as il8ra, predictively targeted by rno-
miR-667 with two possible canonical bindings: 7mer-A1
and 8mer). Ccl3 is a cytokine gene located on chromo-
some 10 of the rat genome; it encodes CCL3, a protein
that binds to several chemokine receptors, including che-
mokine binding protein 2 and chemokine (C-C motif)
receptor 5. Cxcr1 encodes CXCR1, which is a receptor
for IL-8.
Genes related to ion transport potentially targeted by
rno-miR-138 that have been linked with pain states
include the transient receptor potential cation channel,
subfamily C, member 1 (Trpc1) (8mer canonical binding)
located on chromosome 8 in the rat genome. This is a
nonspecific cation channel that contributes to nociceptor
sensitisation.66 The enrichment analysis of rat miRNAs
also identified predictive target genes involved in the
Wnt signalling pathway. This pathway is known to par-
ticipate in the regulation of neuron repulsion during
axonal guidance and thus may be of relevance in axon
regeneration following injury.67
Predictive targets of human miRNAs. Predictive target gene
enrichment analysis of differentially expressed human
miRNAs indicates that potassium voltage-gated chan-
nels are potentially targeted by hsa-miR-500a; thus,
this miRNA may contribute to the regulation of several
potassium channels. Many studies have demonstrated
the role of potassium channels in diseases including
pain.68,69 Genes predicted to be targeted by hsa-miR-
500a include Kcna1, a gene located on chromosome 12
in the human genome that encodes for the potassium
voltage-gated channel subfamily A member 1 (in addi-
tion to 8mer and 7mer-m8, a poorly conserved 6mer
binding site is also predicted). Kcnj1 (located in human
genome chromosome 11) codes for an inwardly rectify-
ing potassium channel (subfamily J) and is also predicted
to be targeted by hsa-miR-500a (7mer-m8 canoni-
cal binding).
hsa-miR-29a was predicted to target genes that regu-
late inflammatory and immune mechanisms, mainly
genes that encode G protein-coupled receptors
(GPCRs) and IL receptors. For instance, the gene
FPR2, located on chromosome 19, is a predicted
target for this miRNA (an 8mer canonical binding).
FPR2/ALX (a GPCR) is the related protein, and previ-
ous studies showed that activation of FPR2/ALX
stopped the recruitment of neutrophils, facilitated reso-
lution of inflammation and inhibited the release of cyto-
kines and chemokines.70,71 Other studies suggest a
role for FPR2/ALX in inhibiting pain processing.72–74
This receptor is classified as a multirecognition receptor
as it binds to multiple molecules including lipoxin A4,
resolvin D1, peptides and proteins (annexin and serum
amyloid A), showing a ligand-specific effect.75,76 FPR2/
ALX has been reported to be regulated by, at least, one
other miRNA, the miR-181b, in human macrophages.77
Methodological considerations
The sample sizes used in this study were relatively small,
and this may explain the slight variation between the
initial TLDA screening and the validation studies.
However, despite the small sample sizes, clear correla-
tions were shown between miRNA expression levels and
drinking behaviour in rats, or VAS scores in patients.
It should also be noted that the human neuromas had
been fixed and stored at –80C for periods of several
months before miRNA extraction and analysis.
However, several studies have demonstrated that
miRNA is more stable than mRNA in fixed samples.78–81
The bioinformatics analysis was based on predicted targets
rather than experimentally validated assays. However, the
TargetScan algorithm used to predict targets in this study
has been shown to have high concordance with experi-
mental validation82 and has the advantage of giving
genome-wide insight.
Different miRNAs were identified in the rat and in
the human lingual nerve samples used; however, the
miRNAs identified have predicted target genes involved
in similar pathways. One possible explanation is the fact
that rat lingual nerve tissues were collected and analysed
in a specific time point (three days following injury), and
human lingual neuroma tissues had variable time points
between injury and tissue analysis (ranging from 7 to 36
months). miRNA expression is a dynamic process, and
there is evidence that miRNAs can change in expression
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over time in the same tissue and pain condition.9
Furthermore, literature has suggested that the develop-
ment and the maintenance of chronic pain is controlled
by differing molecular mechanisms,83,84 denoting that
different miRNAs may be involved at different stages.
Summary
In summary, this study has demonstrated that specific
miRNAs are differentially expressed in injured lingual
nerves and that there are highly significant correlations
between abundance of specific miRNAs, altered behav-
iour and pain VAS scores. To our knowledge, this is the
first demonstration of correlations between human
miRNA levels and VAS scores for neuropathic pain.
Predictive analyses suggested that these miRNAs may
interact with target genes that participate in inflammatory
and signal transduction pathways and axon regrowth and
thus may contribute to the molecular changes that occur
after a peripheral nerve injury. Further functional studies
are planned to evaluate possible physiological effects of
these miRNAs in pain mechanisms.
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